

Notice for Investors in the AXA Framlington Biotech Fund and the AXA Framlington Health Fund

Chris Eccles has joined AXA IM as portfolio manager, bolstering the Equity Healthcare team. Chris joins from Impax Asset Management where he was a senior global healthcare equity analyst, specialising in sustainable investment strategies.

Chris Eccles and Cinney Zhang will co-manage the AXA Framlington Biotech Fund and the AXA Framlington Health Fund alongside their responsibilities co-managing AXA IM Wave Biotech Fund.

Linden Thomson, portfolio manager, will be leaving AXA IM in February 2024. She will work closely with the AXA IM Equity team to ensure a smooth transition. Cinney was already a portfolio manager on the Biotech and Health funds, providing continuity.

Capital at risk. The value of investments and any income from them may fall as well as rise and investors may get back less than they originally invested.

Important information

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

Before making an investment, investors should read the relevant Prospectus and the Key Investor Information Document / scheme documents, which provide full product details including investment charges and risks. The information contained herein is not a substitute for those documents or for professional external advice. The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site https://www.axa-im.com/en/registration-map, where a fund registration map is available. In particular units of the funds may not be offered, sold or delivered to U.S. Persons within the meaning of Regulation S of the U.S. Securities Act of 1933. The tax treatment relating to the holding, acquisition or disposal of shares or units in the fund depends on each investor's tax status or treatment and may be subject to change. Any potential investor is strongly encouraged to seek advice from its own tax advisers.

For more information on sustainability-related aspects please visit https://www.axa-im.com/what-is-sfdr

For investors located in the European Union:

Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in the European Union by filing a notification to its supervision authority, in accordance with European passport rules.

In the event of dissatisfaction with AXA Investment Managers products or services, you have the right to make a complaint, either with the marketer or directly with the management company (more information on AXA IM complaints policy is available in English: https://www.axa-im.com/important-information/comments-and-complaints). If you reside in one of the European Union countries, you also have the right to take legal or extra-judicial action at any time. The European online dispute resolution platform allows you to submit a complaint form (available at: https://ec.europa.eu/consumers/odr/main/index.cfm?event=main.home.chooseLanguage) and provides you with information on available means of redress (available at:

https://ec.europa.eu/consumers/odr/main/?event=main.adr.show2).

Summary of investor rights in English is available on AXA IM website https://www.axa-im.com/important-information/summary-investor-rights. Translations into other languages are available on local AXA IM entities' websites.

Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 22 Bishopsgate London EC2N 4BQ

In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.